drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00290 | DB15066 | 329 | 445 | [
"DDInter219",
"DDInter821"
] | Bleomycin | Givosiran | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders. | Moderate | 1 | [
[
[
329,
24,
445
]
],
[
[
329,
24,
1555
],
[
1555,
24,
445
]
],
[
[
329,
25,
850
],
[
850,
24,
445
]
],
[
[
329,
25,
1377
],
[
1377,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Givosiran
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Ifosfamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Givosiran |
DB00635 | DB06186 | 1,573 | 1,439 | [
"DDInter1515",
"DDInter969"
] | Prednisone | Ipilimumab | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Moderate | 1 | [
[
[
1573,
24,
1439
]
],
[
[
1573,
1,
617
],
[
617,
24,
1439
]
],
[
[
1573,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
1573,
63,
1560
],
[
1560,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderat... | Prednisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab |
DB00994 | DB01112 | 361 | 665 | [
"DDInter1277",
"DDInter335"
] | Neomycin | Cefuroxime | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.[A175042,A191529] Neomycin A, or [neamine], is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Moderate | 1 | [
[
[
361,
24,
665
]
],
[
[
361,
24,
1323
],
[
1323,
1,
665
]
],
[
[
361,
63,
149
],
[
149,
40,
665
]
],
[
[
361,
63,
1087
],
[
1087,
... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefonicid"
],
[
"... | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefonicid and Cefonicid (Compound) resembles Cefuroxime (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefuroxime (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefuroxime (Compound)
Neomycin (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cefuroxime (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime
Neomycin (Compound) resembles Kanamycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefonicid and Cefonicid (Compound) resembles Cephaloglycin (Compound) and Cephaloglycin (Compound) resembles Cefuroxime (Compound) |
DB00277 | DB00467 | 1,031 | 1,467 | [
"DDInter1791",
"DDInter644"
] | Theophylline | Enoxacin | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Major | 2 | [
[
[
1031,
25,
1467
]
],
[
[
1031,
24,
1539
],
[
1539,
40,
1467
]
],
[
[
1031,
6,
7950
],
[
7950,
45,
1467
]
],
[
[
1031,
7,
5415
],
[
5415... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) resembles Enoxacin (Compound)
Theophylline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Enoxacin (Compound)
Theophylline (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Enoxacin (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin
Theophylline may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin |
DB08916 | DB12457 | 26 | 1,180 | [
"DDInter32",
"DDInter1598"
] | Afatinib | Rimegepant | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim. | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists that possessed oral bioavailability until the approval of [atogepant] in 2021. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.[A189330,A189207] | Moderate | 1 | [
[
[
26,
24,
1180
]
],
[
[
26,
24,
741
],
[
741,
24,
1180
]
],
[
[
26,
63,
292
],
[
292,
24,
1180
]
],
[
[
26,
24,
1501
],
[
1501,
63... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib (Compound) resembles Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant |
DB00741 | DB11827 | 167 | 433 | [
"DDInter885",
"DDInter669"
] | Hydrocortisone | Ertugliflozin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
167,
24,
433
]
],
[
[
167,
25,
646
],
[
646,
24,
433
]
],
[
[
167,
63,
1020
],
[
1020,
24,
433
]
],
[
[
167,
24,
1654
],
[
1654,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
],
[
"... | Hydrocortisone may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
DB00860 | DB09237 | 891 | 1,586 | [
"DDInter1513",
"DDInter1045"
] | Prednisolone | Levamlodipine | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. | Moderate | 1 | [
[
[
891,
24,
1586
]
],
[
[
891,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
891,
24,
549
],
[
549,
24,
1586
]
],
[
[
891,
40,
870
],
[
870,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methyl
Prednisolone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Levamlodipine
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Levamlodipine |
DB00500 | DB00631 | 24 | 372 | [
"DDInter1831",
"DDInter405"
] | Tolmetin | Clofarabine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
24,
24,
372
]
],
[
[
24,
6,
7720
],
[
7720,
46,
372
]
],
[
[
24,
7,
3727
],
[
3727,
46,
372
]
],
[
[
24,
21,
28882
],
[
28882,
6... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Tolmetin",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)"... | Tolmetin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Tolmetin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Clofarabine (Compound)
Tolmetin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Clofarabine (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tolmetin may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tolmetin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tolmetin (Compound) resembles Tolcapone (Compound) and Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine |
DB06207 | DB08865 | 910 | 1,593 | [
"DDInter1667",
"DDInter448"
] | Silodosin | Crizotinib | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
910,
24,
1593
]
],
[
[
910,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
910,
21,
28792
],
[
28792,
60,
1593
]
],
[
[
910,
24,
283
],
[
283,
... | [
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Silodosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Silodosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Silodosin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Crizotinib (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Crizotinib |
DB01175 | DB09073 | 318 | 951 | [
"DDInter672",
"DDInter1379"
] | Escitalopram | Palbociclib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Minor | 0 | [
[
[
318,
23,
951
]
],
[
[
318,
40,
1230
],
[
1230,
23,
951
]
],
[
[
318,
23,
159
],
[
159,
63,
951
]
],
[
[
318,
24,
283
],
[
283,
6... | [
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
]
],
[
[
"Escitalopram",
"{u} (Compound) resembles {v} (Compound)",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a mino... | Escitalopram (Compound) resembles Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib |
DB00734 | DB00916 | 1,664 | 112 | [
"DDInter1605",
"DDInter1202"
] | Risperidone | Metronidazole | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Minor | 0 | [
[
[
1664,
23,
112
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
112
]
],
[
[
1664,
21,
28692
],
[
28692,
60,
112
]
],
[
[
1664,
63,
618
],
[
618,
... | [
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Risperidone (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole |
DB00675 | DB06209 | 888 | 256 | [
"DDInter1744",
"DDInter1508"
] | Tamoxifen | Prasugrel | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Minor | 0 | [
[
[
888,
23,
256
]
],
[
[
888,
6,
10215
],
[
10215,
45,
256
]
],
[
[
888,
21,
28681
],
[
28681,
60,
256
]
],
[
[
888,
64,
752
],
[
752,
... | [
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Tamoxifen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Halothane and Halothane may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Tamoxifen may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Tamoxifen may lead to a major life threatening interaction when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel |
DB00524 | DB00855 | 811 | 213 | [
"DDInter1199",
"DDInter72"
] | Metolazone | Aminolevulinic acid | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
811,
25,
213
]
],
[
[
811,
21,
28722
],
[
28722,
60,
213
]
],
[
[
811,
24,
848
],
[
848,
64,
213
]
],
[
[
811,
23,
1572
],
[
1572,
... | [
[
[
"Metolazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (C... | Metolazone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Aminolevulinic acid (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone (Compound) resembles Indapamide (Compound) and Indapamide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Metolazone may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may lead to a major life threatening interaction when taken with Aminolevulinic acid |
DB00631 | DB06212 | 372 | 165 | [
"DDInter405",
"DDInter1833"
] | Clofarabine | Tolvaptan | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
372,
24,
165
]
],
[
[
372,
63,
522
],
[
522,
1,
165
]
],
[
[
372,
21,
28771
],
[
28771,
60,
165
]
],
[
[
372,
24,
267
],
[
267,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) resembles Tolvaptan (Compound)
Clofarabine (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Tolvaptan (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Clofarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan
Clofarabine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tolvaptan
Clofarabine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Tolvaptan
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Tolvaptan |
DB01599 | DB11730 | 1,232 | 351 | [
"DDInter1523",
"DDInter1588"
] | Probucol | Ribociclib | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
1232,
25,
351
]
],
[
[
1232,
62,
112
],
[
112,
23,
351
]
],
[
[
1232,
63,
355
],
[
355,
24,
351
]
],
[
[
1232,
24,
1491
],
[
1491,
... | [
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Ribociclib
Probucol may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Ribociclib
Probucol may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Ribociclib
Probucol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Ribociclib |
DB06704 | DB09135 | 247 | 1,211 | [
"DDInter952",
"DDInter967"
] | Iobenguane (I-131) | Ioxilan | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
247,
25,
1211
]
],
[
[
247,
64,
17
],
[
17,
24,
1211
]
],
[
[
247,
76,
1523
],
[
1523,
24,
1211
]
],
[
[
247,
24,
242
],
[
242,
... | [
[
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause ... | Iobenguane may lead to a major life threatening interaction when taken with Ioxilan
Iobenguane may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Iobenguane may lead to a major life threatening interaction when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Pamidronic acid and Pamidronic acid may lead to a major life threatening interaction when taken with Ioxilan
Iobenguane may lead to a major life threatening interaction when taken with Sotalol and Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may lead to a major life threatening interaction when taken with Pindolol and Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may lead to a major life threatening interaction when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Iobenguane may lead to a major life threatening interaction when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan |
DB00220 | DB06595 | 798 | 1,491 | [
"DDInter1276",
"DDInter1214"
] | Nelfinavir | Midostaurin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Major | 2 | [
[
[
798,
25,
1491
]
],
[
[
798,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
798,
24,
761
],
[
761,
24,
1491
]
],
[
[
798,
25,
1017
],
[
1017,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} ma... | Nelfinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Nelfinavir may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Midostaurin
Nelfinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Midostaurin |
DB00731 | DB11228 | 1,144 | 721 | [
"DDInter1269",
"DDInter1184"
] | Nateglinide | Methylcellulose | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values are 1.3 2.6. Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel. It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic | Minor | 0 | [
[
[
1144,
23,
721
]
],
[
[
1144,
24,
1411
],
[
1411,
23,
721
]
],
[
[
1144,
63,
245
],
[
245,
23,
721
]
],
[
[
1144,
24,
1411
],
[
1411,
... | [
[
[
"Nateglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Nateglinide (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose |
DB00631 | DB00694 | 372 | 51 | [
"DDInter405",
"DDInter485"
] | Clofarabine | Daunorubicin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
372,
24,
51
]
],
[
[
372,
5,
11555
],
[
11555,
44,
51
]
],
[
[
372,
6,
17404
],
[
17404,
45,
51
]
],
[
[
372,
7,
3363
],
[
3363,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Clofarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Di... | Clofarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Daunorubicin (Compound)
Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Daunorubicin (Compound)
Clofarabine (Compound) upregulates NFKBIB (Gene) and NFKBIB (Gene) is upregulated by Daunorubicin (Compound)
Clofarabine (Compound) downregulates PHKB (Gene) and PHKB (Gene) is upregulated by Daunorubicin (Compound)
Clofarabine (Compound) downregulates AURKA (Gene) and AURKA (Gene) is downregulated by Daunorubicin (Compound)
Clofarabine (Compound) upregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Daunorubicin (Compound)
Clofarabine (Compound) causes Skin hyperpigmentation (Side Effect) and Skin hyperpigmentation (Side Effect) is caused by Daunorubicin (Compound)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Daunorubicin |
DB00496 | DB01010 | 194 | 61 | [
"DDInter480",
"DDInter622"
] | Darifenacin | Edrophonium | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
194,
24,
61
]
],
[
[
194,
21,
28658
],
[
28658,
60,
61
]
],
[
[
194,
24,
1511
],
[
1511,
63,
61
]
],
[
[
194,
24,
1507
],
[
1507,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Darifenacin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is cau... | Darifenacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Edrophonium (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Darifenacin (Compound) resembles Clidinium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Darifenacin (Compound) resembles Trospium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Darifenacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Phenylephrine (Compound) and Phenylephrine (Compound) resembles Edrophonium (Compound)
Darifenacin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Tapentadol (Compound) and Tapentadol (Compound) resembles Edrophonium (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Edrophonium (Compound) |
DB00731 | DB01095 | 1,144 | 671 | [
"DDInter1269",
"DDInter769"
] | Nateglinide | Fluvastatin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. | Moderate | 1 | [
[
[
1144,
24,
671
]
],
[
[
1144,
6,
4610
],
[
4610,
45,
671
]
],
[
[
1144,
21,
28681
],
[
28681,
60,
671
]
],
[
[
1144,
63,
126
],
[
126,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"SLC15A1"
],
[
"SLC15A1",
"{u} (Gene) is bound by {v} (Compou... | Nateglinide (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Fluvastatin (Compound)
Nateglinide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fluvastatin (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Fluvastatin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Fluvastatin
Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin |
DB00086 | DB00790 | 1,167 | 664 | [
"DDInter1712",
"DDInter1431"
] | Streptokinase | Perindopril | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. | Moderate | 1 | [
[
[
1167,
24,
664
]
],
[
[
1167,
24,
1638
],
[
1638,
1,
664
]
],
[
[
1167,
24,
954
],
[
954,
40,
664
]
],
[
[
1167,
24,
885
],
[
885,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Streptokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Perindopril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound) and Trandolapril (Compound) resembles Perindopril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Streptokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound) |
DB00470 | DB01116 | 530 | 601 | [
"DDInter601",
"DDInter1872"
] | Dronabinol | Trimethaphan | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
530,
24,
601
]
],
[
[
530,
63,
357
],
[
357,
1,
601
]
],
[
[
530,
24,
537
],
[
537,
1,
601
]
],
[
[
530,
24,
1264
],
[
1264,
63,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine (Compound) resembles Trimethaphan (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Trimethaphan (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Trimethaphan
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Trimethaphan (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Trimethaphan (Compound) |
DB00060 | DB06317 | 912 | 1,626 | [
"DDInter947",
"DDInter630"
] | Interferon beta-1a | Elotuzumab | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
912,
24,
1626
]
],
[
[
912,
24,
1463
],
[
1463,
24,
1626
]
],
[
[
912,
24,
1468
],
[
1468,
63,
1626
]
],
[
[
912,
63,
1451
],
[
1451,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Interferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Elotuzumab
Interferon beta-1a may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Elotuzumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Elotuzumab
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab |
DB00909 | DB01075 | 306 | 1,376 | [
"DDInter1971",
"DDInter569"
] | Zonisamide | Diphenhydramine | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Major | 2 | [
[
[
306,
25,
1376
]
],
[
[
306,
24,
649
],
[
649,
63,
1376
]
],
[
[
306,
64,
128
],
[
128,
24,
1376
]
],
[
[
306,
25,
401
],
[
401,
... | [
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofe... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide may lead to a major life threatening interaction when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Diphenhydramine (Compound)
Zonisamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide may lead to a major life threatening interaction when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Zonisamide may lead to a major life threatening interaction when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Diphenhydramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine |
DB01232 | DB06616 | 1,327 | 594 | [
"DDInter1640",
"DDInter224"
] | Saquinavir | Bosutinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Major | 2 | [
[
[
1327,
25,
594
]
],
[
[
1327,
63,
883
],
[
883,
1,
594
]
],
[
[
1327,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1327,
21,
29231
],
[
29231,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Saquinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Saquinavir (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Saquinavir may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Saquinavir may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Saquinavir may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00374 | DB08822 | 1,061 | 911 | [
"DDInter1852",
"DDInter156"
] | Treprostinil | Azilsartan medoxomil | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure. | Moderate | 1 | [
[
[
1061,
24,
911
]
],
[
[
1061,
63,
217
],
[
217,
1,
911
]
],
[
[
1061,
24,
240
],
[
240,
1,
911
]
],
[
[
1061,
21,
29081
],
[
29081,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Azilsartan medoxomil (Compound)
Treprostinil (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Azilsartan medoxomil (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Treprostinil may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Treprostinil (Compound) resembles Epoprostenol (Compound) and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound) |
DB00852 | DB03754 | 1,445 | 1,400 | [
"DDInter1545",
"DDInter1883"
] | Pseudoephedrine | Tromethamine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) | Moderate | 1 | [
[
[
1445,
24,
1400
]
],
[
[
1445,
24,
959
],
[
959,
23,
1400
]
],
[
[
1445,
63,
590
],
[
590,
23,
1400
]
],
[
[
1445,
63,
1360
],
[
1360,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tromethamine"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Mecamylamine and Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Pseudoephedrine (Compound) resembles Dextroamphetamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine and Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Tromethamine |
DB00552 | DB01030 | 1,238 | 869 | [
"DDInter1425",
"DDInter1835"
] | Pentostatin | Topotecan | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1238,
24,
869
]
],
[
[
1238,
21,
29276
],
[
29276,
60,
869
]
],
[
[
1238,
23,
872
],
[
872,
62,
869
]
],
[
[
1238,
62,
1467
],
[
1467,... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Pentostatin",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is... | Pentostatin (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound)
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pentostatin (Compound) resembles Cladribine (Compound) and Pentostatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Pentostatin (Compound) resembles Floxuridine (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan |
DB00531 | DB00731 | 450 | 1,144 | [
"DDInter456",
"DDInter1269"
] | Cyclophosphamide | Nateglinide | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. | Moderate | 1 | [
[
[
450,
24,
1144
]
],
[
[
450,
6,
6799
],
[
6799,
45,
1144
]
],
[
[
450,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
450,
24,
1033
],
[
1033,... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v}... | Cyclophosphamide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Nateglinide (Compound)
Cyclophosphamide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide (Compound) resembles Ifosfamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide |
DB00238 | DB14723 | 188 | 159 | [
"DDInter1285",
"DDInter1026"
] | Nevirapine | Larotrectinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
188,
24,
159
]
],
[
[
188,
24,
222
],
[
222,
23,
159
]
],
[
[
188,
24,
741
],
[
741,
24,
159
]
],
[
[
188,
63,
912
],
[
912,
24,... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nevirapine may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nevirapine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Larotrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB09570 | DB15093 | 1,480 | 1,654 | [
"DDInter1002",
"DDInter1698"
] | Ixazomib | Somapacitan | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
1480,
24,
1654
]
],
[
[
1480,
63,
168
],
[
168,
23,
1654
]
],
[
[
1480,
63,
10
],
[
10,
24,
1654
]
],
[
[
1480,
24,
214
],
[
214,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ixazomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ixazomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00146 | DB09146 | 160 | 489 | [
"DDInter265",
"DDInter978"
] | Calcifediol | Iron sucrose | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. | Moderate | 1 | [
[
[
160,
24,
489
]
],
[
[
160,
36,
386
],
[
386,
24,
489
]
],
[
[
160,
25,
1331
],
[
1331,
24,
489
]
],
[
[
160,
25,
241
],
[
241,
6... | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
... | Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Iron sucrose
Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol (Compound) resembles Ergocalciferol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol (Compound) resembles Cholecalciferol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Cholecalciferol (Compound) and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Calcifediol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol (Compound) resembles Ergocalciferol (Compound) and Paricalcitol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose |
DB06288 | DB12332 | 607 | 1,619 | [
"DDInter77",
"DDInter1626"
] | Amisulpride | Rucaparib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Major | 2 | [
[
[
607,
25,
1619
]
],
[
[
607,
62,
112
],
[
112,
23,
1619
]
],
[
[
607,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
607,
64,
888
],
[
888,
... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amisulpride may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amisulpride may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amisulpride may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib
Amisulpride may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Amisulpride may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Rucaparib
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB01058 | DB01138 | 978 | 804 | [
"DDInter1510",
"DDInter1726"
] | Praziquantel | Sulfinpyrazone | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030.[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated. | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
978,
24,
804
]
],
[
[
978,
63,
998
],
[
998,
1,
804
]
],
[
[
978,
6,
8374
],
[
8374,
45,
804
]
],
[
[
978,
18,
4930
],
[
4930,
5... | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Praziquantel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfinpyrazone (Compound)
Praziquantel (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Sulfinpyrazone (Compound)
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Praziquantel may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfinpyrazone (Compound)
Praziquantel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clotrimazole (Compound) and Clotrimazole (Compound) resembles Sulfinpyrazone (Compound)
Praziquantel (Compound) downregulates DLD (Gene) and DLD (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Sulfinpyrazone (Compound) |
DB00420 | DB01409 | 508 | 1,415 | [
"DDInter1532",
"DDInter1815"
] | Promazine | Tiotropium | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004. | Moderate | 1 | [
[
[
508,
24,
1415
]
],
[
[
508,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
508,
1,
146
],
[
146,
24,
1415
]
],
[
[
508,
63,
1594
],
[
1594,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Promazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine (Compound) resembles Chlorpheniramine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium (Compound) resembles Tiotropium (Compound) and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Promazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Methylscopolamine bromide (Compound) and Methylscopolamine bromide (Compound) resembles Tiotropium (Compound) |
DB01023 | DB08816 | 409 | 578 | [
"DDInter716",
"DDInter1802"
] | Felodipine | Ticagrelor | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Minor | 0 | [
[
[
409,
23,
578
]
],
[
[
409,
6,
4973
],
[
4973,
45,
578
]
],
[
[
409,
21,
28645
],
[
28645,
60,
578
]
],
[
[
409,
1,
336
],
[
336,
... | [
[
[
"Felodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Felodipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Felodipine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Felodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Felodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Felodipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB01377 | DB09101 | 1,283 | 70 | [
"DDInter1119",
"DDInter633"
] | Magnesium oxide | Elvitegravir | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug. Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. On September 24, 2014, the FDA approved the single pill form of elvitegravir. | Moderate | 1 | [
[
[
1283,
24,
70
]
],
[
[
1283,
24,
286
],
[
286,
63,
70
]
],
[
[
1283,
24,
1040
],
[
1040,
24,
70
]
],
[
[
1283,
62,
1220
],
[
1220,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elvitegravir"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydro... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir |
DB01142 | DB01403 | 1,264 | 9 | [
"DDInter593",
"DDInter1175"
] | Doxepin | Methotrimeprazine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1264,
24,
9
]
],
[
[
1264,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1264,
74,
1164
],
[
1164,
1,
9
]
],
[
[
1264,
40,
11233
],
[
11233,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Doxepin (Compound) resembles Trimipramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Methotrimeprazine (Compound)
Doxepin (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Methotrimeprazine (Compound)
Doxepin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Methotrimeprazine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Methotrimeprazine (Compound)
Doxepin (Compound) resembles Clomipramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Methotrimeprazine (Compound)
Doxepin (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Methotrimeprazine (Compound)
Doxepin (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) is bound by Methotrimeprazine (Compound) |
DB00106 | DB09104 | 618 | 286 | [
"DDInter4",
"DDInter1118"
] | Abarelix | Magnesium hydroxide | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
618,
24,
286
]
],
[
[
618,
24,
401
],
[
401,
23,
286
]
],
[
[
618,
24,
859
],
[
859,
24,
286
]
],
[
[
618,
25,
494
],
[
494,
24,... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Abarelix may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Abarelix may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Abarelix may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Abarelix may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide |
DB01083 | DB06292 | 1,142 | 549 | [
"DDInter1348",
"DDInter474"
] | Orlistat | Dapagliflozin | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021. | Moderate | 1 | [
[
[
1142,
24,
549
]
],
[
[
1142,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1142,
6,
8374
],
[
8374,
45,
549
]
],
[
[
1142,
21,
29222
],
[
29222... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Orlistat (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Orlistat (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Dapagliflozin (Compound)
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) binds UGT1A9 (Gene) and UGT1A9 (Gene) is bound by Dapagliflozin (Compound)
Orlistat (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Orlistat (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound) |
DB00687 | DB01226 | 870 | 1,319 | [
"DDInter747",
"DDInter1235"
] | Fludrocortisone | Mivacurium | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Moderate | 1 | [
[
[
870,
24,
1319
]
],
[
[
870,
24,
648
],
[
648,
1,
1319
]
],
[
[
870,
21,
29232
],
[
29232,
60,
1319
]
],
[
[
870,
63,
1031
],
[
1031,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
]... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Fludrocortisone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Mivacurium (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium
Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium
Fludrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Atracurium (Compound) and Atracurium (Compound) resembles Mivacurium (Compound)
Fludrocortisone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Atracurium (Compound) and Atracurium (Compound) resembles Mivacurium (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound) |
DB00745 | DB00877 | 307 | 629 | [
"DDInter1236",
"DDInter1678"
] | Modafinil | Sirolimus | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
307,
24,
629
]
],
[
[
307,
6,
7524
],
[
7524,
45,
629
]
],
[
[
307,
18,
5415
],
[
5415,
46,
629
]
],
[
[
307,
7,
7626
],
[
7626,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sirolimus (Compound)
Modafinil (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Sirolimus (Compound)
Modafinil (Compound) upregulates IL13RA1 (Gene) and IL13RA1 (Gene) is upregulated by Sirolimus (Compound)
Modafinil (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Sirolimus (Compound)
Modafinil (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Modafinil may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Modafinil (Compound) resembles Levacetylmethadol (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Modafinil may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus |
DB06701 | DB06706 | 1,177 | 468 | [
"DDInter521",
"DDInter985"
] | Dexmethylphenidate | Isometheptene | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture. | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1177,
24,
468
]
],
[
[
1177,
63,
480
],
[
480,
24,
468
]
],
[
[
1177,
24,
144
],
[
144,
63,
468
]
],
[
[
1177,
40,
895
],
[
895,
... | [
[
[
"Dexmethylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Dexmethylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoter... | Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate (Compound) resembles Methylphenidate (Compound) and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Isometheptene
Dexmethylphenidate may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Isometheptene
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Dexmethylphenidate (Compound) resembles Methylphenidate (Compound) and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene |
DB00910 | DB01110 | 1,041 | 86 | [
"DDInter1394",
"DDInter1209"
] | Paricalcitol | Miconazole | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to miconazole among susceptible organisms is relatively low. | Moderate | 1 | [
[
[
1041,
24,
86
]
],
[
[
1041,
6,
8374
],
[
8374,
45,
86
]
],
[
[
1041,
21,
29122
],
[
29122,
60,
86
]
],
[
[
1041,
63,
690
],
[
690,
... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Paricalcitol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Miconazole (Compound)
Paricalcitol (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Paricalcitol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tioconazole (Compound) and Tioconazole (Compound) resembles Miconazole (Compound)
Paricalcitol (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Paricalcitol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Oxiconazole (Compound) and Oxiconazole (Compound) resembles Miconazole (Compound) |
DB00647 | DB12245 | 675 | 823 | [
"DDInter528",
"DDInter1863"
] | Dextropropoxyphene | Triclabendazole | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
675,
24,
823
]
],
[
[
675,
23,
112
],
[
112,
23,
823
]
],
[
[
675,
63,
1010
],
[
1010,
24,
823
]
],
[
[
675,
24,
28
],
[
28,
24,... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronid... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Dextropropoxyphene (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Dextropropoxyphene may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Triclabendazole
Dextropropoxyphene (Compound) resembles Bepridil (Compound) and Bepridil may lead to a major life threatening interaction when taken with Triclabendazole |
DB00731 | DB06016 | 1,144 | 1,508 | [
"DDInter1269",
"DDInter300"
] | Nateglinide | Cariprazine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Moderate | 1 | [
[
[
1144,
24,
1508
]
],
[
[
1144,
63,
600
],
[
600,
24,
1508
]
],
[
[
1144,
24,
1450
],
[
1450,
63,
1508
]
],
[
[
1144,
24,
1021
],
[
1021... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine |
DB06288 | DB09080 | 607 | 144 | [
"DDInter77",
"DDInter1331"
] | Amisulpride | Olodaterol | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
607,
24,
144
]
],
[
[
607,
25,
1011
],
[
1011,
24,
144
]
],
[
[
607,
64,
11
],
[
11,
24,
144
]
],
[
[
607,
63,
543
],
[
543,
24,... | [
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolim... | Amisulpride may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Amisulpride may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Amisulpride may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Amisulpride may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Olodaterol
Amisulpride may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Amisulpride may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol |
DB00622 | DB09036 | 1,081 | 812 | [
"DDInter1287",
"DDInter1668"
] | Nicardipine | Siltuximab | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem] | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Moderate | 1 | [
[
[
1081,
24,
812
]
],
[
[
1081,
24,
259
],
[
259,
24,
812
]
],
[
[
1081,
40,
409
],
[
409,
24,
812
]
],
[
[
1081,
24,
1456
],
[
1456,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nicardipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Nicardipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab |
DB00842 | DB09420 | 686 | 1,074 | [
"DDInter1359",
"DDInter953"
] | Oxazepam | Iodide I-123 | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131. | Moderate | 1 | [
[
[
686,
24,
1074
]
],
[
[
686,
24,
516
],
[
516,
24,
1074
]
],
[
[
686,
1,
902
],
[
902,
24,
1074
]
],
[
[
686,
40,
523
],
[
523,
2... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
... | Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 |
DB00477 | DB06292 | 216 | 549 | [
"DDInter363",
"DDInter474"
] | Chlorpromazine | Dapagliflozin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021. | Moderate | 1 | [
[
[
216,
24,
549
]
],
[
[
216,
24,
1344
],
[
1344,
40,
549
]
],
[
[
216,
6,
8374
],
[
8374,
45,
549
]
],
[
[
216,
21,
29222
],
[
29222,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Chlorpromazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Chlorpromazine (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Dapagliflozin (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Chlorpromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Chlorpromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin |
DB00863 | DB01337 | 1,194 | 1,579 | [
"DDInter1568",
"DDInter1385"
] | Ranitidine | Pancuronium | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Minor | 0 | [
[
[
1194,
23,
1579
]
],
[
[
1194,
62,
1610
],
[
1610,
1,
1579
]
],
[
[
1194,
23,
728
],
[
728,
1,
1579
]
],
[
[
1194,
6,
10715
],
[
10715,... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pancuronium"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rocuronium"
],
[
... | Ranitidine may cause a minor interaction that can limit clinical effects when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vecuronium and Vecuronium (Compound) resembles Pancuronium (Compound)
Ranitidine (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Pancuronium (Compound)
Ranitidine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Pancuronium (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Pancuronium (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vecuronium and Vecuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Pancuronium (Compound)
Ranitidine (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Rocuronium (Compound) and Rocuronium (Compound) resembles Pancuronium (Compound)
Ranitidine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Rocuronium (Compound) and Rocuronium (Compound) resembles Pancuronium (Compound) |
DB00408 | DB00836 | 1,408 | 543 | [
"DDInter1099",
"DDInter1088"
] | Loxapine | Loperamide | An antipsychotic agent used in schizophrenia. [PubChem] | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Moderate | 1 | [
[
[
1408,
24,
543
]
],
[
[
1408,
24,
649
],
[
649,
1,
543
]
],
[
[
1408,
24,
262
],
[
262,
24,
543
]
],
[
[
1408,
63,
1242
],
[
1242,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Loperamide (Compound)
Loxapine (Compound) resembles Azatadine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Loxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide |
DB00493 | DB00798 | 1,087 | 1,132 | [
"DDInter323",
"DDInter815"
] | Cefotaxime | Gentamicin | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use. | Moderate | 1 | [
[
[
1087,
24,
1132
]
],
[
[
1087,
6,
10612
],
[
10612,
45,
1132
]
],
[
[
1087,
21,
28703
],
[
28703,
60,
1132
]
],
[
[
1087,
24,
361
],
[
... | [
[
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
]
],
[
[
"Cefotaxime",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)... | Cefotaxime (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Gentamicin (Compound)
Cefotaxime (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gentamicin (Compound)
Cefotaxime may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime (Compound) resembles Ceftriaxone (Compound) and Ceftriaxone may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime (Compound) resembles Ceftazidime (Compound) and Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime (Compound) resembles Cefixime (Compound) and Cefixime may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Cefotaxime (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Piperacillin (Compound) and Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin |
DB00366 | DB11632 | 1,594 | 580 | [
"DDInter600",
"DDInter1343"
] | Doxylamine | Opicapone | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa. Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 and the FDA in April 2020. It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors. | Moderate | 1 | [
[
[
1594,
24,
580
]
],
[
[
1594,
24,
104
],
[
104,
24,
580
]
],
[
[
1594,
63,
475
],
[
475,
24,
580
]
],
[
[
1594,
74,
701
],
[
701,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opicapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone |
DB00620 | DB01263 | 175 | 859 | [
"DDInter1855",
"DDInter1494"
] | Triamcinolone | Posaconazole | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
175,
25,
859
]
],
[
[
175,
6,
8374
],
[
8374,
45,
859
]
],
[
[
175,
21,
28762
],
[
28762,
60,
859
]
],
[
[
175,
63,
1101
],
[
1101,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Triamcinolone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Triamcinolone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Triamcinolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole |
DB00619 | DB12141 | 1,419 | 971 | [
"DDInter909",
"DDInter817"
] | Imatinib | Gilteritinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1419,
24,
971
]
],
[
[
1419,
25,
1135
],
[
1135,
23,
971
]
],
[
[
1419,
24,
466
],
[
466,
62,
971
]
],
[
[
1419,
24,
1097
],
[
1097,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Imatinib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib |
DB00850 | DB01067 | 1,630 | 959 | [
"DDInter1432",
"DDInter826"
] | Perphenazine | Glipizide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
1630,
24,
959
]
],
[
[
1630,
63,
245
],
[
245,
40,
959
]
],
[
[
1630,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1630,
6,
8374
],
[
8374,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Perphenazine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Glipizide (Compound)
Perphenazine (Compound) upregulates GRN (Gene) and GRN (Gene) is downregulated by Glipizide (Compound)
Perphenazine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Glipizide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00014 | DB00468 | 521 | 1,424 | [
"DDInter839",
"DDInter1557"
] | Goserelin | Quinine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Moderate | 1 | [
[
[
521,
24,
1424
]
],
[
[
521,
21,
29316
],
[
29316,
60,
1424
]
],
[
[
521,
23,
1247
],
[
1247,
62,
1424
]
],
[
[
521,
24,
479
],
[
479,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {... | Goserelin (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Quinine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Goserelin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Quinine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine may lead to a major life threatening interaction when taken with Quinine
Goserelin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Quinine |
DB01611 | DB06317 | 1,487 | 1,626 | [
"DDInter893",
"DDInter630"
] | Hydroxychloroquine | Elotuzumab | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
1487,
24,
1626
]
],
[
[
1487,
63,
973
],
[
973,
24,
1626
]
],
[
[
1487,
24,
310
],
[
310,
63,
1626
]
],
[
[
1487,
62,
663
],
[
663,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may lead to a major life threatening interaction when taken with Sodium aurothiomalate and Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Hydroxychloroquine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Elotuzumab
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab |
DB04843 | DB14881 | 1,511 | 180 | [
"DDInter1149",
"DDInter1329"
] | Mepenzolate | Oliceridine | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
1511,
24,
180
]
],
[
[
1511,
63,
401
],
[
401,
24,
180
]
],
[
[
1511,
40,
649
],
[
649,
24,
180
]
],
[
[
1511,
24,
407
],
[
407,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate (Compound) resembles Loperamide (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Oliceridine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Mepenzolate (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine |
DB01124 | DB09082 | 1,411 | 659 | [
"DDInter1828",
"DDInter1934"
] | Tolbutamide | Vilanterol | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1411,
24,
659
]
],
[
[
1411,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1411,
63,
891
],
[
891,
23,
659
]
],
[
[
1411,
24,
1296
],
[
1296,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol |
DB00282 | DB12865 | 641 | 922 | [
"DDInter1383",
"DDInter688"
] | Pamidronic acid | Etelcalcetide | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming more popular. Pamidronic acid was granted FDA approval on 31 October 1991. | Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. | Major | 2 | [
[
[
641,
25,
922
]
],
[
[
641,
24,
485
],
[
485,
25,
922
]
],
[
[
641,
1,
1485
],
[
1485,
25,
922
]
],
[
[
641,
24,
485
],
[
485,
63... | [
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etelcalcetide"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Torasemide (Compound) and Torasemide may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may lead to a major life threatening interaction when taken with Etelcalcetide
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Etelcalcetide |
DB06589 | DB09154 | 1,250 | 1,475 | [
"DDInter1400",
"DDInter1686"
] | Pazopanib | Sodium citrate | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works by neutralizing excess acid in the blood and urine. It has been indicated for the treatment of metabolic acidosis. | Moderate | 1 | [
[
[
1250,
24,
1475
]
],
[
[
1250,
24,
263
],
[
263,
23,
1475
]
],
[
[
1250,
63,
355
],
[
355,
23,
1475
]
],
[
[
1250,
63,
1539
],
[
1539,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Pazopanib (Compound) resembles Rilpivirine (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Pazopanib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Sodium citrate
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Sodium citrate |
DB00425 | DB12332 | 558 | 1,619 | [
"DDInter1970",
"DDInter1626"
] | Zolpidem | Rucaparib | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
558,
24,
1619
]
],
[
[
558,
24,
222
],
[
222,
23,
1619
]
],
[
[
558,
24,
1419
],
[
1419,
24,
1619
]
],
[
[
558,
24,
159
],
[
159,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Eszopiclone and Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib |
DB01259 | DB14509 | 392 | 1,399 | [
"DDInter1024",
"DDInter1081"
] | Lapatinib | Lithium carbonate | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
392,
24,
1399
]
],
[
[
392,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
392,
63,
820
],
[
820,
24,
1399
]
],
[
[
392,
64,
609
],
[
609,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lapatinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lapatinib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Lapatinib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Lithium carbonate
Lapatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lithium carbonate
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Lithium carbonate
Lapatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lithium carbonate |
DB01284 | DB08822 | 1,042 | 911 | [
"DDInter1782",
"DDInter156"
] | Tetracosactide | Azilsartan medoxomil | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure. | Moderate | 1 | [
[
[
1042,
24,
911
]
],
[
[
1042,
63,
217
],
[
217,
1,
911
]
],
[
[
1042,
24,
1450
],
[
1450,
63,
911
]
],
[
[
1042,
24,
549
],
[
549,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesarta... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Tetracosactide may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Tetracosactide may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) |
DB00515 | DB01169 | 589 | 57 | [
"DDInter387",
"DDInter120"
] | Cisplatin | Arsenic trioxide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
589,
25,
57
]
],
[
[
589,
6,
5912
],
[
5912,
45,
57
]
],
[
[
589,
24,
112
],
[
112,
23,
57
]
],
[
[
589,
63,
1257
],
[
1257,
24,... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Arsen... | Cisplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Arsenic trioxide (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Cisplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Cisplatin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Arsenic trioxide
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Arsenic trioxide
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Arsenic trioxide
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB00683 | DB08865 | 1,382 | 1,593 | [
"DDInter1212",
"DDInter448"
] | Midazolam | Crizotinib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
1382,
24,
1593
]
],
[
[
1382,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1382,
18,
16974
],
[
16974,
57,
1593
]
],
[
[
1382,
21,
28771
],
[
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Midazolam (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Crizotinib (Compound)
Midazolam (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Midazolam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB00661 | DB01156 | 122 | 593 | [
"DDInter1928",
"DDInter252"
] | Verapamil | Bupropion | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. | Moderate | 1 | [
[
[
122,
24,
593
]
],
[
[
122,
6,
3486
],
[
3486,
45,
593
]
],
[
[
122,
21,
28757
],
[
28757,
60,
593
]
],
[
[
122,
63,
752
],
[
752,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Verapamil (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Verapamil may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may lead to a major life threatening interaction when taken with Bupropion
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may lead to a major life threatening interaction when taken with Bupropion
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may lead to a major life threatening interaction when taken with Bupropion
Verapamil may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Bupropion |
DB01072 | DB01211 | 915 | 609 | [
"DDInter129",
"DDInter393"
] | Atazanavir | Clarithromycin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
915,
24,
609
]
],
[
[
915,
6,
4973
],
[
4973,
45,
609
]
],
[
[
915,
54,
19146
],
[
19146,
15,
609
]
],
[
[
915,
21,
28759
],
[
28759,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Atazanavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Atazanavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Clarithromycin (Compound)
Atazanavir (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Atazanavir may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Atazanavir may lead to a major life threatening interaction when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00420 | DB00468 | 508 | 1,424 | [
"DDInter1532",
"DDInter1557"
] | Promazine | Quinine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Moderate | 1 | [
[
[
508,
24,
1424
]
],
[
[
508,
6,
6017
],
[
6017,
45,
1424
]
],
[
[
508,
23,
112
],
[
112,
62,
1424
]
],
[
[
508,
24,
1254
],
[
1254,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quinine (Compound)
Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine (Compound) resembles Tamoxifen (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Promazine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Quinine |
DB00372 | DB08824 | 999 | 591 | [
"DDInter1793",
"DDInter959"
] | Thiethylperazine | Ioflupane I-123 | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
999,
24,
591
]
],
[
[
999,
24,
109
],
[
109,
24,
591
]
],
[
[
999,
25,
684
],
[
684,
24,
591
]
],
[
[
999,
63,
867
],
[
867,
24,... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Ioflupane I-123 (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam and Fenoldopam (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ioflupane I-123 (Compound)
Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ioflupane I-123 (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine and Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 |
DB00092 | DB00603 | 58 | 303 | [
"DDInter40",
"DDInter1137"
] | Alefacept | Medroxyprogesterone acetate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959. | Moderate | 1 | [
[
[
58,
24,
303
]
],
[
[
58,
24,
167
],
[
167,
1,
303
]
],
[
[
58,
24,
700
],
[
700,
62,
303
]
],
[
[
58,
63,
305
],
[
305,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortiso... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Alefacept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Alefacept may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate |
DB00220 | DB00741 | 798 | 167 | [
"DDInter1276",
"DDInter885"
] | Nelfinavir | Hydrocortisone | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
798,
24,
167
]
],
[
[
798,
24,
1220
],
[
1220,
40,
167
]
],
[
[
798,
63,
1351
],
[
1351,
40,
167
]
],
[
[
798,
25,
617
],
[
617,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Hydrocortisone (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Budesonide and Budesonide (Compound) resembles Hydrocortisone (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Nelfinavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Hydrocortisone (Compound)
Nelfinavir (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Hydrocortisone (Compound)
Nelfinavir (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Hydrocortisone (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone |
DB00348 | DB09054 | 254 | 384 | [
"DDInter1300",
"DDInter905"
] | Nitisinone | Idelalisib | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
254,
24,
384
]
],
[
[
254,
24,
555
],
[
555,
23,
384
]
],
[
[
254,
23,
307
],
[
307,
23,
384
]
],
[
[
254,
63,
1023
],
[
1023,
2... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Nitisinone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin and Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Idelalisib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB00641 | DB06636 | 467 | 1,623 | [
"DDInter1675",
"DDInter980"
] | Simvastatin | Isavuconazonium | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications. | Moderate | 1 | [
[
[
467,
24,
1623
]
],
[
[
467,
24,
466
],
[
466,
62,
1623
]
],
[
[
467,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
467,
24,
309
],
[
309,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Simvastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Simvastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Isavuconazonium
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Isavuconazonium
Simvastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Isavuconazonium |
DB00675 | DB12267 | 888 | 1,476 | [
"DDInter1744",
"DDInter233"
] | Tamoxifen | Brigatinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
888,
24,
1476
]
],
[
[
888,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
888,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
888,
24,
629
],
[
629,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tamoxifen (Compound) resembles Levacetylmethadol (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib |
DB00364 | DB00978 | 417 | 739 | [
"DDInter1717",
"DDInter1084"
] | Sucralfate | Lomefloxacin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
417,
24,
739
]
],
[
[
417,
24,
945
],
[
945,
40,
739
]
],
[
[
417,
63,
1176
],
[
1176,
1,
739
]
],
[
[
417,
24,
1299
],
[
1299,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Lomefloxacin (Compound)
Sucralfate (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Lomefloxacin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin |
DB00294 | DB09045 | 1,336 | 52 | [
"DDInter701",
"DDInter607"
] | Etonogestrel | Dulaglutide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
1336,
24,
52
]
],
[
[
1336,
24,
170
],
[
170,
23,
52
]
],
[
[
1336,
24,
609
],
[
609,
24,
52
]
],
[
[
1336,
40,
35
],
[
35,
24,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Etonogestrel (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Etonogestrel may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Etonogestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Dulaglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide |
DB06702 | DB12332 | 573 | 1,619 | [
"DDInter731",
"DDInter1626"
] | Fesoterodine | Rucaparib | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
573,
24,
1619
]
],
[
[
573,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
573,
24,
159
],
[
159,
63,
1619
]
],
[
[
573,
24,
913
],
[
913,
... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Rucaparib
Fesoterodine (Compound) resembles Disopyramide (Compound) and Disopyramide may lead to a major life threatening interaction when taken with Rucaparib |
DB00046 | DB01069 | 1,179 | 401 | [
"DDInter940",
"DDInter1533"
] | Insulin lispro | Promethazine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
1179,
24,
401
]
],
[
[
1179,
24,
146
],
[
146,
24,
401
]
],
[
[
1179,
24,
820
],
[
820,
63,
401
]
],
[
[
1179,
24,
1247
],
[
1247,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Promethazine
Insulin lispro may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may lead to a major life threatening interaction when taken with Promethazine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Promethazine |
DB00741 | DB11866 | 167 | 1,068 | [
"DDInter885",
"DDInter1618"
] | Hydrocortisone | Romosozumab | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924]. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide. Romosozumab is marketed in the United States by Amgen under the brand name Evinity. Romosozumab was granted FDA approval on April 9,2019. | Moderate | 1 | [
[
[
167,
24,
1068
]
],
[
[
167,
25,
770
],
[
770,
24,
1068
]
],
[
[
167,
40,
870
],
[
870,
24,
1068
]
],
[
[
167,
1,
1486
],
[
1486,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"... | Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab |
DB00719 | DB01591 | 1,219 | 667 | [
"DDInter149",
"DDInter1696"
] | Azatadine | Solifenacin | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1219,
24,
667
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1219,
40,
830
],
[
830,
63,
667
]
],
[
[
1219,
24,
1123
],
[
1123,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Azatadine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Solifenacin
Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mequitazine (Compound) and Mequitazine (Compound) resembles Solifenacin (Compound)
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Solifenacin (Compound) |
DB00774 | DB11113 | 1,577 | 657 | [
"DDInter889",
"DDInter307"
] | Hydroflumethiazide | Castor oil | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
1577,
24,
657
]
],
[
[
1577,
24,
891
],
[
891,
24,
657
]
],
[
[
1577,
63,
613
],
[
613,
24,
657
]
],
[
[
1577,
40,
674
],
[
674,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolon... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB00344 | DB12332 | 1,302 | 1,619 | [
"DDInter1543",
"DDInter1626"
] | Protriptyline | Rucaparib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1302,
24,
1619
]
],
[
[
1302,
25,
222
],
[
222,
23,
1619
]
],
[
[
1302,
23,
112
],
[
112,
23,
1619
]
],
[
[
1302,
24,
1662
],
[
1662,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibu... | Protriptyline may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Protriptyline may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib |
DB08873 | DB11837 | 74 | 1,297 | [
"DDInter221",
"DDInter1351"
] | Boceprevir | Osilodrostat | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Major | 2 | [
[
[
74,
25,
1297
]
],
[
[
74,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
74,
24,
466
],
[
466,
62,
1297
]
],
[
[
74,
25,
1320
],
[
1320,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Boceprevir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Boceprevir may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat |
DB00586 | DB01045 | 1,512 | 463 | [
"DDInter537",
"DDInter1590"
] | Diclofenac | Rifampicin | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Moderate | 1 | [
[
[
1512,
24,
463
]
],
[
[
1512,
6,
7950
],
[
7950,
45,
463
]
],
[
[
1512,
24,
738
],
[
738,
63,
463
]
],
[
[
1512,
63,
1645
],
[
1645,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Diclofenac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rifampicin (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Diclofenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Diclofenac may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Diclofenac may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Rifampicin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Rifampicin
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Rifampicin |
DB00495 | DB00694 | 139 | 51 | [
"DDInter1961",
"DDInter485"
] | Zidovudine | Daunorubicin | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
139,
24,
51
]
],
[
[
139,
6,
4973
],
[
4973,
45,
51
]
],
[
[
139,
6,
5441
],
[
5441,
46,
51
]
],
[
[
139,
18,
8800
],
[
8800,
57... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Zidovudine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Daunorubicin (Compound)
Zidovudine (Compound) binds TERT (Gene) and TERT (Gene) is upregulated by Daunorubicin (Compound)
Zidovudine (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Daunorubicin (Compound)
Zidovudine (Compound) causes Sickness (Side Effect) and Sickness (Side Effect) is caused by Daunorubicin (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Zidovudine (Compound) resembles Floxuridine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin |
DB00673 | DB06702 | 723 | 573 | [
"DDInter112",
"DDInter731"
] | Aprepitant | Fesoterodine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
723,
24,
573
]
],
[
[
723,
24,
211
],
[
211,
1,
573
]
],
[
[
723,
63,
494
],
[
494,
1,
573
]
],
[
[
723,
6,
8374
],
[
8374,
45,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fesoterodine (Compound)
Aprepitant (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fesoterodine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Aprepitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine
Aprepitant may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine |
DB00501 | DB12240 | 752 | 110 | [
"DDInter380",
"DDInter1485"
] | Cimetidine | Polatuzumab vedotin | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020. | Moderate | 1 | [
[
[
752,
24,
110
]
],
[
[
752,
24,
467
],
[
467,
24,
110
]
],
[
[
752,
25,
1213
],
[
1213,
24,
110
]
],
[
[
752,
23,
458
],
[
458,
2... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin |
DB01041 | DB01208 | 770 | 945 | [
"DDInter1789",
"DDInter1705"
] | Thalidomide | Sparfloxacin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Moderate | 1 | [
[
[
770,
24,
945
]
],
[
[
770,
63,
739
],
[
739,
1,
945
]
],
[
[
770,
24,
1539
],
[
1539,
1,
945
]
],
[
[
770,
21,
29006
],
[
29006,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) resembles Sparfloxacin (Compound)
Thalidomide (Compound) causes Albuminuria (Side Effect) and Albuminuria (Side Effect) is caused by Sparfloxacin (Compound)
Thalidomide may lead to a major life threatening interaction when taken with Temozolomide and Temozolomide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Thalidomide may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Thalidomide may lead to a major life threatening interaction when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Thalidomide may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin |
DB00307 | DB11627 | 1,101 | 1,367 | [
"DDInter202",
"DDInter860"
] | Bexarotene | Hepatitis B Vaccine (Recombinant) | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
1101,
24,
1367
]
],
[
[
1101,
64,
1560
],
[
1560,
24,
1367
]
],
[
[
1101,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
1101,
25,
375
],
[
375... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
]... | Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB00992 | DB05239 | 842 | 866 | [
"DDInter1182",
"DDInter425"
] | Methyl aminolevulinate (topical) | Cobimetinib | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Moderate | 1 | [
[
[
842,
24,
866
]
],
[
[
842,
24,
33
],
[
33,
24,
866
]
],
[
[
842,
24,
785
],
[
785,
63,
866
]
],
[
[
842,
63,
1101
],
[
1101,
24,... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Am... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Cobimetinib
Methyl aminolevulinate (Compound) resembles Aminolevulinic acid (Compound) and Methyl aminolevulinate may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib |
DB00683 | DB09073 | 1,382 | 951 | [
"DDInter1212",
"DDInter1379"
] | Midazolam | Palbociclib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Moderate | 1 | [
[
[
1382,
24,
951
]
],
[
[
1382,
24,
1476
],
[
1476,
63,
951
]
],
[
[
1382,
24,
259
],
[
259,
24,
951
]
],
[
[
1382,
64,
600
],
[
600,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Midazolam may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Midazolam may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Palbociclib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib
Midazolam may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Palbociclib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Palbociclib |
DB00377 | DB01208 | 1,494 | 945 | [
"DDInter1382",
"DDInter1705"
] | Palonosetron | Sparfloxacin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
1494,
25,
945
]
],
[
[
1494,
24,
739
],
[
739,
1,
945
]
],
[
[
1494,
64,
1176
],
[
1176,
1,
945
]
],
[
[
1494,
25,
246
],
[
246,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lo... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin (Compound) resembles Sparfloxacin (Compound)
Palonosetron (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Sparfloxacin (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Palonosetron may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin
Palonosetron may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Sparfloxacin |
DB01142 | DB09241 | 1,264 | 1,629 | [
"DDInter593",
"DDInter1186"
] | Doxepin | Methylene blue | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
1264,
25,
1629
]
],
[
[
1264,
63,
1052
],
[
1052,
24,
1629
]
],
[
[
1264,
64,
532
],
[
532,
24,
1629
]
],
[
[
1264,
24,
697
],
[
697,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Doxepin may lead to a major life threatening interaction when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Doxepin may lead to a major life threatening interaction when taken with Levonordefrin and Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Doxepin may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may lead to a major life threatening interaction when taken with Methylene blue
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine may lead to a major life threatening interaction when taken with Methylene blue
Doxepin may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Methylene blue |
DB00163 | DB01234 | 1,461 | 1,220 | [
"DDInter1943",
"DDInter513"
] | Vitamin E | Dexamethasone | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Minor | 0 | [
[
[
1461,
23,
1220
]
],
[
[
1461,
23,
175
],
[
175,
40,
1220
]
],
[
[
1461,
23,
167
],
[
167,
1,
1220
]
],
[
[
1461,
7,
2384
],
[
2384,
... | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],
[
... | Vitamin E may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Dexamethasone (Compound)
Vitamin E (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Dexamethasone (Compound)
Vitamin E (Compound) downregulates SPRED2 (Gene) and SPRED2 (Gene) is downregulated by Dexamethasone (Compound)
Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Dexamethasone (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone |
DB00712 | DB00855 | 1,274 | 213 | [
"DDInter763",
"DDInter72"
] | Flurbiprofen | Aminolevulinic acid | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1274,
25,
213
]
],
[
[
1274,
21,
28880
],
[
28880,
60,
213
]
],
[
[
1274,
24,
1577
],
[
1577,
25,
213
]
],
[
[
1274,
24,
1040
],
[
104... | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is caus... | Flurbiprofen (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Aminolevulinic acid (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate (Compound) resembles Aminolevulinic acid (Compound) and Methyl aminolevulinate may lead to a major life threatening interaction when taken with Aminolevulinic acid
Flurbiprofen (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by L-Glutamine (Compound) and L-Glutamine (Compound) resembles Aminolevulinic acid (Compound) |
DB06702 | DB08912 | 573 | 1,040 | [
"DDInter731",
"DDInter462"
] | Fesoterodine | Dabrafenib | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
573,
24,
1040
]
],
[
[
573,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
573,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
573,
63,
1101
],
[
1101,... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Fesoterodine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Fesoterodine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Fesoterodine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Fesoterodine (Compound) resembles Disopyramide (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Fesoterodine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Fesoterodine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.